These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23981258)

  • 1. How can the quality of medical data in pharmacovigilance, pharmacoepidemiology and clinical studies be guaranteed?
    Alla F; Rosilio M; Funck-Brentano C; ; Barthélémy P; Brisset S; Cellier D; Chassany O; Demarez JP; Diebolt V; Francillon A; Gambotti L; Hannachi H; Lechat P; Lemaire F; Lièvre M; Misse C; Nguon M; Pariente A; Rosenheim M; Weisslinger-Darmon N
    Therapie; 2013; 68(4):209-23. PubMed ID: 23981258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Translation and introduction of Guide to Methodological Standards in Pharmacoepidemiology].
    Tian F; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2949-57. PubMed ID: 24471310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal detection in pharmacovigilance: empirical evaluation of data mining tools.
    Chan KA; Hauben M
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):597-9. PubMed ID: 16134080
    [No Abstract]   [Full Text] [Related]  

  • 4. [The GCP directive--consequences for clinical drug research].
    Gluud CN
    Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacovigilance of medicinal products in Poland--new guidelines].
    Jabłecka A; Korzeniowska K; Balcer-Dymel N
    Przegl Lek; 2012; 69(10):1127-8. PubMed ID: 23421106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance systems and databases in Korea, Japan, and Taiwan.
    Kimura T; Matsushita Y; Yang YH; Choi NK; Park BJ
    Pharmacoepidemiol Drug Saf; 2011 Dec; 20(12):1237-45. PubMed ID: 21936017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia.
    ; Andersen M; Bergman U; Choi NK; Gerhard T; Huang C; Jalbert J; Kimura M; Kimura T; Kubota K; Lai EC; Ooba N; Park BJ; Pratt N; Roughead EE; Sato T; Setoguchi S; Shin JY; Sundström A; Yang YH
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):700-4. PubMed ID: 23653370
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidelines for good database selection and use in pharmacoepidemiology research.
    Hall GC; Sauer B; Bourke A; Brown JS; Reynolds MW; LoCasale R
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):1-10. PubMed ID: 22069180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of pharmacovigilance system in Ukraine: first results.
    Stefanov O; Sharayeva M; Jajtchenja V
    Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):197-9. PubMed ID: 15072120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
    Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.
    Hauben M; Reich L
    J Clin Pharmacol; 2005 Apr; 45(4):378-84. PubMed ID: 15778418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade.
    Tsuchiya M; Obara T; Miyazaki M; Noda A; Takamura C; Mano N
    Int J Clin Pharm; 2020 Apr; 42(2):728-736. PubMed ID: 32020439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data mining for signals in spontaneous reporting databases: proceed with caution.
    Stephenson WP; Hauben M
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):359-65. PubMed ID: 17019675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size of the reference sample in a case-augmented study.
    Ghosh P; Dewanji A
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):528-534. PubMed ID: 28295862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis.
    Kshirsagar N; Ferner R; Figueroa BA; Ghalib H; Lazdin J
    Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):61-7. PubMed ID: 21185045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Building quality in clinical trials with use of a quality systems approach.
    Kleppinger CF; Ball LK
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S111-6. PubMed ID: 20597658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries.
    Pratt N; Chan EW; Choi NK; Kimura M; Kimura T; Kubota K; Lai EC; Man KK; Ooba N; Park BJ; Sato T; Shin JY; Wong IC; Kao Yang YH; Roughead EE
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):858-64. PubMed ID: 25907076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.